A study assessing outcomes for the three FDA-approved BCMA-directed bispecific antibodies indicated for relapsed or refractory multiple myeloma (MM) found that linvoseltamab resulted in numerically higher rates of complete response or better and had a lower incidence of cytokine release syndrome (CRS).
Ayse Gul Korkmaz, MD, of USF Morsani School of Medicine HCA Florida Oak Hill Hospital, and colleagues presented the findings at the 2026 SOHO Annual Meeting.
They performed an exploratory cross-trial analysis of the three pivotal trials:
- MajesTEC-1 for teclistamab (n=165)
- MagnetisMM-3 for elranatamab (n=123)
- LINKER-MM1 for linvoseltamab (n=117)
The overall response rate was 63% with teclistamab, 61% with elranatamab, and 71% with linvoseltamab, including CR or better occurring in 39.4%, 35.0%, and 52.0% of patients, respectively.
The median duration of response was 18.4 months for teclistamab and 29.4 months for linvoseltamab. Median progression-free survival was 11.3 months for teclistamab and not reached with elranatamab or linvoseltamab.
CRS occurred in 72.1% of patients receiving teclistamab, 57.7% receiving elranatamab, and 46.0% receiving linvoseltamab, all of which were commonly low-grade. Immune effector cell-associated neurotoxicity syndrome was uncommon across treatment options.
However, infection risk was substantial, with grade ≥3 infections occurring in 44.8% in the teclistamab cohort, 39.8% in the elranatamab group, and 48.0% in the linvoseltamab cohort.
The researchers noted that because the data were derived from separate single-arm studies, superiority across the regimens could not be determined.
Reference
Korkmaz AG, Patel D, Dharia A, Chaudhari J, Salman M. Efficacy and safety of approved BCMA-directed bispecific antibodies in triple-class-exposed relapsed/refractory multiple myeloma: an exploratory cross-trial comparison. Abstract MM-774. Presented at the 2026 Society of Hematologic Oncology Annual Meeting; September 9-12, 2026; Houston.
Leave feedback about this